Journal Mobile Options
Table of Contents
Vol. 35, No. 5-6, 1999
Issue release date: May–June 1999

Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility

Ross R.K. · Coetzee G.A. · Pearce C.L. · Reichardt J.K.V. · Bretsky P. · Kolonel L.N. · Henderson B.E. · Lander E. · Altshuler D. · Daley G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The prostate is an androgen-regulated organ, which has led to longstanding interest in the role of androgens in prostate carcinogenesis. Although evidence of a hormonal etiology for prostate cancer is strong, it is almost entirely circumstantial. Much of the problem in proving a causal relationship relates to the continued difficulties in reliably measuring human tissue-specific exposure to endogenous steroid hormones. The international and racial-ethnic variations in prostate cancer incidence, combined with the effects of migration on risk patterns, have suggested that genetic factors play a central role in determining prostate cancer risk. We are developing a polygenic model of prostate carcinogenesis, focused around a series of genes involved in androgen biosynthesis, transport and metabolism. We have begun to develop this model by utilizing sequence variants to study how polymorphic markers in two genes (SRD5A2 and AR) are related to prostate cancer risk within and between racial-ethnic groups. We are now collaborating with the Whitehead Institute/MIT, Center for Genome Research, to screen for single nucleotide polymorphisms in additional genes relevant to the androgen pathway and prostate cell growth. The model when fully developed can potentially provide a basis for targeting populations for screening interventions and for implementing primary preventive strategies.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bittner JJ: The causes and control of mammary cancer in mice. Harvey Lect 1947;42:221–246.
  2. Huggins C, Hodges CV: Studies on prostatic cancer: Effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–297.
  3. Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN and Henderson BE: Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility. Cancer Res 1998 October 15;58:4497–4504.
  4. Cook PJ, Doll R, Fellingham SA: A mathematical model for the age distribution of cancer in man. Int J Cancer 1969;4:93–112.

    External Resources

  5. Ross RK, Schottenfeld D: Prostate cancer; in Schottenfeld D, Fraumeni J (eds): Cancer Epidemiology and Prevention, ed 2. Oxford, Oxford University Press, 1996, pp 1180–1206.
  6. Kehinde EO: The geography of prostate cancer and its treatment in Africa. Cancer Surv 1995;23:281–286.
  7. Shimizu H, Ross RK, Bernstein L: Underestimation of the incidence rate of prostate cancer in Japan. Jpn J Cancer Res 1991;82:483–485.
  8. Bernstein L, Ross RK: Cancer in Los Angeles County. A Portrait of Incidence and Mortality, 1972–1987. Kenneth Norris Jr Comprehensive Cancer Center, University of Southern California, Los Angeles 1991.
  9. Henderson BE, Ross RK, Bernstein L: Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246–253.

    External Resources

  10. Preston-Martin S, Pike MC, Ross RK, Henderson BE: Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Perspect 1993;101(suppl 5):137–138.
  11. Coffey DS: The molecular biology of the prostate; in Lepor H, Lawson RK (eds): Prostate Disease. Philadelphia, Saunders, 1993, pp 28–56.
  12. Noble RL: The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929–1933.
  13. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118–1126.
  14. Ross RK, Bernstein L, Judd H, Hanisch R, Pike MC, Henderson BE: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45–48.

    External Resources

  15. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE: 5α-Reductase activity and risk of prostate cancer among Japanese and US White and Black males. Lancet 1992;339:887–889.
  16. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ: Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991;72:1242–1248.
  17. Ross RK, Coetzee GA: The epidemiology and etiology of prostate cancer; in Petrovich Z, Baert L, Brady LW (eds): Diagnostic Imaging and Radiation Oncology. Berlin, Springer, 1996, pp 1–11.
  18. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371–1374.
  19. Norman AW, Litwack G: Steroid hormones: Chemistry, biosynthesis, and metabolism; in Hormones, ed 2. New York, Academic Press, 1997, pp 1–71.
  20. Kolonel LN, Henderson BE, Hankin JH, Nomura AMY, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS: A multiethnic cohort in Hawaii and Los Angeles: Baseline characteristics. Am J Epidemiol 1999, in press.
  21. Wilson JD, Griffin JE, Russell DW: Steroid 5α-reductase 2 deficiency. Br J Cancer 1993;14:577–593.
  22. Thigpen AE, Davis DL, Gautier T, Imperato-McGinley J, Russell DW: The molecular basis of steroid 5-alpha reductase deficiency in a large Dominican kindred. N Engl J Med 1992;327:1216–1219.
  23. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi C-Y, Yu MC, Henderson BE, Reichardt JKV: A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res 1997;57:1020–1022.
  24. Reichardt JKV, Makridakis NM, Ross RK, Pike MC, Kolonel LC, Henderson BE: A missense mutation in the SRD5A2 gene with a significant population-attributable risk for clinically apparent prostate cancer through increased dihydrotestosterone biosynthesis (in review).
  25. Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937–1940.
  26. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77–79.
  27. Tut TG, Ghadessey FJ, Trifiro MA, Pinsky L, Yong EL: Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;3777–3782.
  28. Coetzee GA, Ross RK: Prostate cancer and the androgen receptor. J Natl Cancer Inst 1994;86:872–873.
  29. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166–170.
  30. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF: Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset. J Clin Endocrinol Metab 1996;81:4400–4405.
  31. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk. Cancer Res 1997;57:1194–1198.
  32. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320–3323.
  33. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER: Androgen receptor variants with short glutamine or glycine repeats identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997;3:1599–1608.
  34. Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, Henderson BE: Evidence of an X-linked genetic component to prostate cancer risk. Nat Med 1995;1:827–829.

    External Resources

  35. Narod SA, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu R, Labrie F: The impact of family history on early detection of prostate cancer. Nat Med 1995;1:99–101.
  36. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J, Grönberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175–179.
  37. Lu J, Danielsen D: Short report on DNA marker at candidate locus: A StuI polymorphism in the human androgen receptor gene. Clin Genet 1996;49:323–324.
  38. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, Kruglyak L, Stein L, Hsie L, Topaloglou T, Hubbell E, Robinson E, Mittmann M, Morris MS, Shen N, Kilburn D, Rioux J, Nusbaum C, Rozen S, Hudson TJ, Lipshutz R, Chee M, Lander ES: Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998;280:1077–1082.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50